Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

SINGAPORE (Reuters) -Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Markets are assessing the reshaped US trade landscape after Trump on Thursday laid out steep new tariffs for dozens of ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

The report comes a day after President Trump sent a series of letters to top U.S. healthcare company CEOs insisting that they lower the prices of important treatments. If implemented, this apparent ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...